This category covers biotechnology and pharmaceutical companies developing therapies targeting synaptic dysfunction in Parkinson's disease. Synaptic dysfunction represents one of the earliest pathological features in PD, preceding dopaminergic neuron loss by years or decades[1]. The synapse relies on precisely coordinated processes including neurotransmitter synthesis, vesicle trafficking, release, and recycling—all of which become disrupted in PD through alpha-synuclein pathology, mitochondrial dysfunction, lysosomal impairment, and neuroinflammation[2].
| Mechanism | Description | Companies |
|---|---|---|
| Dopamine packaging (VMAT2) | Vesicular monoamine transporter function | VMAT Modulators |
| Dopamine receptor signaling | D1/D2 receptor agonists and modulators | PD GPCR Signaling |
| Mitochondrial function | Synaptic energy metabolism | Mitochondrial Neuroprotection |
| Autophagy-lysosomal | Synaptic protein clearance | Lysosomal/Autophagy |
| Calcium homeostasis | Synaptic calcium regulation | Ion Channel Modulators |
The vesicular monoamine transporter 2 (VMAT2) packages dopamine into synaptic vesicles, protecting it from oxidative degradation and enabling regulated release. VMAT2 modulators can enhance dopamine packaging efficiency.
Dopamine receptor agonists directly stimulate postsynaptic dopamine receptors to compensate for reduced dopaminergic neurotransmission.
Synaptic activity is extraordinarily energy-intensive, requiring constant ATP generation. Mitochondrial dysfunction compromises synaptic energy supply, making mitochondrial protectants relevant for synaptic restoration.
Alpha-synuclein oligomers directly bind to synaptic vesicles, impairing neurotransmitter release[3]. Companies targeting alpha-synuclein aggregation indirectly protect synaptic function.
The lysosomal-autophagy pathway is essential for synaptic protein turnover and organelle quality control. Enhancing autophagy can clear toxic synaptic proteins.
Dopaminergic neurons exhibit rhythmic pacemaking activity relying on L-type calcium channels. Calcium dysregulation triggers downstream toxic pathways at synapses.
The SNARE complex (syntaxin-1, SNAP-25, synaptobrevin/VAMP2) mediates synaptic vesicle fusion. While research shows SNARE proteins are altered in PD[4], there are few companies explicitly targeting this mechanism. This represents a potential therapeutic gap.
Synaptic vesicle proteins including synaptotagmin, SV2, and synaptophysin are reduced in PD. Gene therapy approaches to restore these proteins could preserve synaptic function but remain largely unexplored commercially.
Small molecules that enhance neurotransmitter release probability without causing excess release could help compensate for synaptic dysfunction. This approach is still in early research stages.
Companies developing SV2A PET ligands (like synaptic vesicle glycoprotein 2A imaging) enable visualization of synaptic density[@matuskey2020], which can guide clinical development of synaptic-protective therapies.
| Company | Drug | Mechanism | Phase | Status |
|---|---|---|---|---|
| Neurocrine | Valbenazine | VMAT2 modulation | Approved (TD), Phase 2 (PD) | Active |
| Teva | Deutetrabenazine | VMAT2 inhibition | Approved | Active |
| Kyowa Kirin | Rotigotine | D1/D2 agonist | Approved | Active |
| Kyowa Kirin | Istradefylline | A2A antagonist | Approved (Japan) | Active |
| Clene | CNM-Au8 | Catalytic antioxidant | Phase 2 | Active |
| NeuroMito | NMT-101 | Mitochondrial antioxidant | Phase 2 | Active |
| Prothena | PRX002 | Anti-αSyn antibody | Phase 2 | Active |
| Biogen | BIIB054 | Anti-αSyn antibody | Phase 2 | Completed |
| Denali | DNL151 | LRRK2 inhibitor | Phase 2b | Active |
| Gain | GT-02287 | GCase modulator | Phase 1b | Active |
| Modag | Anle138b | αSyn aggregation inhibitor | Phase 1 | Active |
Synaptic dysfunction in Parkinson's disease involves multiple convergent mechanisms:
Preserving or restoring synaptic function represents a promising disease-modifying approach:
Cheng HC, Ulane CM, Burke RE. Clinical progression of Parkinson's disease and the neurobiology of axons. Ann Neurol. 2010. ↩︎
Bellucci A, et al. Synaptic dysfunction in Parkinson's disease: from alpha-synuclein pathology to synaptic protein loss. Prog Neuropsychopharmacol Biol Psychiatry. 2020. ↩︎
Wang L, et al. Alpha-synuclein oligomers bind to synaptic vesicles and inhibit neurotransmitter release. J Biol Chem. 2017. ↩︎ ↩︎
Rodriguez-Perea ER, et al. SNARE proteins in Parkinson's disease. Neurology. 2020. ↩︎